Glucose-lowering treatment in cardiovascular and peripheral artery disease

DPP-4 inh. indicates dipeptidyl peptidase-4 inhibitors; GLP-1 RA, glucagon-like peptide-1 receptor agonist; MET, metformin; SLGT2i, sodium glucose cotransporter 2 inhibitors; SU, sulfonylureas; TZD, thiazolidinediones.